- Home
- PHGE vs CELZ Comparison
PHGE vs CELZ Comparison
Compare PHGE & CELZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- CELZ
- Stock Information
- Founded
- PHGE 2015
- CELZ 1998
- Country
- PHGE Israel
- CELZ United States
- Employees
- PHGE N/A
- CELZ N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- CELZ Biotechnology: Pharmaceutical Preparations
- Sector
- PHGE Health Care
- CELZ Health Care
- Exchange
- PHGE Nasdaq
- CELZ Nasdaq
- Market Cap
- PHGE 13.0M
- CELZ 10.4M
- IPO Year
- PHGE N/A
- CELZ N/A
- Fundamental
- Price
- PHGE $0.31
- CELZ $3.09
- Analyst Decision
- PHGE Strong Buy
- CELZ
- Analyst Count
- PHGE 1
- CELZ 0
- Target Price
- PHGE $15.00
- CELZ N/A
- AVG Volume (30 Days)
- PHGE 1.7M
- CELZ 169.9K
- Earning Date
- PHGE 11-12-2025
- CELZ 11-07-2025
- Dividend Yield
- PHGE N/A
- CELZ N/A
- EPS Growth
- PHGE N/A
- CELZ N/A
- EPS
- PHGE N/A
- CELZ N/A
- Revenue
- PHGE N/A
- CELZ $6,000.00
- Revenue This Year
- PHGE N/A
- CELZ N/A
- Revenue Next Year
- PHGE N/A
- CELZ N/A
- P/E Ratio
- PHGE N/A
- CELZ N/A
- Revenue Growth
- PHGE N/A
- CELZ N/A
- 52 Week Low
- PHGE $0.31
- CELZ $1.69
- 52 Week High
- PHGE $1.16
- CELZ $6.90
- Technical
- Relative Strength Index (RSI)
- PHGE 27.31
- CELZ 45.24
- Support Level
- PHGE $0.35
- CELZ $2.77
- Resistance Level
- PHGE $0.42
- CELZ $3.34
- Average True Range (ATR)
- PHGE 0.04
- CELZ 0.47
- MACD
- PHGE -0.01
- CELZ -0.05
- Stochastic Oscillator
- PHGE 2.81
- CELZ 17.24
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.